Why GLP-1 Weight Loss Stalls, and What Actually Works

If your weight loss has slowed or stopped on a GLP-1, the first thing worth knowing is that this is not unusual, and it is not automatically a sign the medication has "stopped working." Plateaus were built into the trial data from the start — here is what the evidence actually shows and what is worth checking before assuming something is wrong.

The trials themselves show a plateau curve, not a straight line

Weight loss on semaglutide and tirzepatide is not linear — it is steep early, then flattens. In STEP-1, the roughly 15% mean weight reduction at 68 weeks did not happen at a constant monthly rate; the curve rises quickly through the first several months, especially as dosing reaches its maintenance level, then gradually levels off toward the end of the trial period¹. SURMOUNT-1 shows the same overall shape at higher magnitude — up to roughly 21% at tirzepatide's top dose over 72 weeks². A plateau in the later months of treatment is not a deviation from the trial data; it is what the trial data itself looks like.

Why this happens, mechanistically

Semaglutide and tirzepatide work primarily by reducing appetite and food intake — a mechanistic study of semaglutide found measurable reductions in energy intake, hunger, and food cravings that track with the weight-loss response³. As body weight drops, energy expenditure drops too — a smaller body simply burns fewer calories at rest, a well-established physiological response to weight loss that applies regardless of method. At some point, the reduced calorie intake the drug is producing and the reduced calorie burn of a smaller body converge into a new equilibrium — which is, functionally, a plateau. This is not the drug failing; it is the expected point where intake and expenditure balance out at your new weight, absent some other change.

What to actually check before assuming the drug "stopped working"

**Are you still at your intended maintenance dose, and has it been long enough?** Both labeled titration schedules take months to reach full maintenance dose — our titration planner shows exactly where you should be by week. A plateau while still mid-titration is a different situation than a plateau after months at full maintenance dose.

**Has anything about your intake or activity shifted?** As appetite suppression continues, it is easy to unconsciously drift back toward old eating patterns once the initial dramatic effect feels normal — worth an honest look before assuming the pharmacology has changed.

**Are you on the right molecule for your goals?** Tirzepatide produced measurably more weight loss than semaglutide head-to-head in the SURPASS-2 diabetes trial and in the separate obesity-trial comparisons¹² — see our full semaglutide-versus-tirzepatide breakdown. Some people plateau on one molecule and see further loss after switching to the other, though this is an individual response, not a guarantee.

**Is your dose actually the labeled maintenance dose, or did you or your provider stop escalating early?** Providers that tier dosing to hit a cheaper price point rather than a clinically appropriate one are exactly the kind of practice our what compounded GLP-1 costs per month guide warns about — a plateau caused by an undersized maintenance dose is a different problem than a genuine physiological one, and worth ruling out with your prescriber.

When to talk to your prescriber, not just wait it out

A plateau that follows the expected shape above is not an emergency. But real weight regain while still on the medication, or a plateau reached unusually early relative to your titration timeline, is worth a direct conversation — there may be a dose adjustment, molecule switch, or other factor worth reviewing, and that conversation is exactly what ongoing member support should provide.

Where this fits into choosing a provider

A provider that disappears after your first shipment cannot help you work through a plateau; one with genuine ongoing support can. That is precisely why member support and prescriber access are scored factors in our Verdict Score methodology — see how providers compare in the ranked reviews.

This is editorial information, not medical advice. Discuss a weight-loss plateau, dose changes, or a molecule switch with your prescribing clinician.